104 results match your criteria Parkinson-Plus Syndromes


Dysphagia in Parkinsonism: Prevalence, Predictors and Correlation with Severity of Illness Fasting).

J Assoc Physicians India 2020 May;68(5):22-25

Associate Professor, Department of Medicine, LTMMC and GH, Mumbai, Maharashtra.

Introduction: Dysphagia is frequently present in Parkinsonian syndromes and is associated with increased morbidity and mortality. Early identification of swallowing dysfunction is critical to minimize complications like aspiration pneumonia and malnutrition. Published prevalence rates for dysphagia in Parkinsonian syndromes vary widely with a very few studies from India. Read More

View Article

Download full-text PDF

Source

Overview of sleep disturbances and their management in Parkinson plus disorders.

J Neurol Sci 2020 May 8;415:116891. Epub 2020 May 8.

Department of Neurology, National Institute of Mental Health & Neurosciences (NIMHANS), Hosur Road, Bangalore, Karnataka 560029, India. Electronic address:

Sleep disturbance is one of the commonly reported non-motor symptoms in patients with Parkinson's disease (PD) as well as in Parkinson plus disorders such as multiple system atrophy (MSA), dementia with Lewy bodies (DLB), progressive supranuclear palsy (PSP), and corticobasal syndrome (CBS). Although there is a wealth of literature on sleep disturbances in PD, the same is not robust on the Parkinson plus disorders. This article aims to comprehensively review the sleep disturbances in Parkinson plus disorders. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2020.116891DOI Listing

DCTN1-related Parkinson-plus disorder (Perry syndrome).

Pract Neurol 2020 May 20. Epub 2020 May 20.

Department of Neurology, St George's Hospital, London, UK

Dynactin-1 (DCTN1)-related Parkinson-plus disorder (Perry syndrome) is an autosomal dominant neurodegenerative disorder characterised by levodopa-resistant parkinsonism, weight loss, mood change and central hypoventilation. Ventilatory insufficiency is the predominant cause of death. It has been previously described in 87 people from 20 families with a worldwide distribution. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/practneurol-2020-002505DOI Listing

Locus coeruleus pathology in progressive supranuclear palsy, and its relation to disease severity.

Acta Neuropathol Commun 2020 02 4;8(1):11. Epub 2020 Feb 4.

Cambridge University Centre for Parkinson-plus and Department of Clinical Neurosciences, University of Cambridge, Robinson Way, Cambridge, CB2 0SZ, UK.

The locus coeruleus is the major source of noradrenaline to the brain and contributes to a wide range of physiological and cognitive functions including arousal, attention, autonomic control, and adaptive behaviour. Neurodegeneration and pathological aggregation of tau protein in the locus coeruleus are early features of progressive supranuclear palsy (PSP). This pathology is proposed to contribute to the clinical expression of disease, including the PSP Richardson's syndrome. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40478-020-0886-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7001334PMC
February 2020

Parkinsonism in frontotemporal dementias.

Authors:
James B Rowe

Int Rev Neurobiol 2019 21;149:249-275. Epub 2019 Nov 21.

Cambridge University Centre for Frontotemporal Dementia and Cambridge University Centre for Parkinson-plus, Cambridge University, Cambridge, United Kingdom.

Frontotemporal dementia is a clinically and pathologically heterogeneous group of neurodegenerative disorders, with progressive impairment of behavior and language. They can be closely related to amyotrophic lateral sclerosis, clinically and through shared genetics and similar pathology. Approximately 40% of people with frontotemporal dementia report a family history of dementia, motor neuron disease or parkinsonism, and half of these familial cases are attributed to mutations in three genes (C9orf72, MAPT and PGRN). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/bs.irn.2019.10.012DOI Listing

Urological function and dysfunction in aging: Diagnosis and treatment.

Handb Clin Neurol 2019 ;167:495-509

Center for Health in Aging, Emory University School of Medicine, Atlanta, GA, United States.

Urinary symptoms worsen further the quality of life of persons already burdened by neurologic disease. Urinary symptoms frequently occur in the setting of neurologic diseases such as Parkinson disease and Parkinson-plus syndromes, multiple sclerosis, and stroke. Urinary incontinence is associated with increased caregiver burden and enhances the risk of institutionalization among those living with dementia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/B978-0-12-804766-8.00027-3DOI Listing

Recognizing and treating atypical Parkinson disorders.

Handb Clin Neurol 2019 ;167:301-320

Department of Neurology, University of Florida College of Medicine, Gainesville, FL, United States.

Though less common than Parkinson's disease (PD), the atypical Parkinson disorders such as such as dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, and corticobasal degeneration are increasingly recognized and important to distinguish from PD. Atypical or "Parkinson-plus" disorders are multisystem disorders and generally progress more rapidly and respond poorly to current therapies compared to PD. Recent advances in our understanding of the pathophysiology of these disorders, however, have generated new interest in the development of novel diagnostics and disease-modifying therapeutics aimed at identifying and treating these disorders. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/B978-0-12-804766-8.00016-9DOI Listing

Dysphagia in Progressive Supranuclear Palsy.

Dysphagia 2019 Nov 1. Epub 2019 Nov 1.

Department of Neurology, Mayo Clinic, 200 1st Street S.W., Rochester, MN, 55905, USA.

Progressive supranuclear palsy (PSP) is the most common Parkinson-Plus syndrome and is associated with early onset of dysphagia relative to Parkinson Disease. The current study contributes to the growing understanding of swallowing dysfunction in PSP by describing oropharyngeal swallowing characteristics in a large prospective cohort of participants with PSP employing a nationally standardized videofluoroscopy protocol and a disease severity scale developed expressly for PSP. Participants were 51 adults diagnosed with PSP. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00455-019-10073-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192765PMC
November 2019
1 Read

Survival, effect measures, and impact numbers after dementia diagnosis: a matched cohort study.

Clin Epidemiol 2019 16;11:525-542. Epub 2019 Jul 16.

Research Group on Ageing, Disability and Health, Girona Biomedical Research Institute (IDIBGI), Catalonia, Spain.

Background: Knowledge on survival after diagnosis is important for all stakeholders. We aimed to estimate the survival and life expectancy after a dementia diagnosis, and to quantify the impact of dementia subtypes on mortality.

Methods: Retrospective matched cohort study using a linkage between a dementia-specific registry and two primary care electronic medical records databases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/CLEP.S213228DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6645613PMC
July 2019
2 Reads

What Predicts Hospital Admissions in Community-Dwelling People With Parkinsonism?

J Geriatr Psychiatry Neurol 2020 Mar 13;33(2):103-108. Epub 2019 Aug 13.

Northumbria Healthcare NHS Foundation Trust, North Tyneside General Hospital, Rake Lane, North Shields, Tyne and Wear, United Kingdom.

Objectives: Previous studies have looked at the reasons for hospital admission in people with parkinsonism (PwP), yet few have looked at factors that precipitate admission.

Methods: People with parkinsonism with a diagnosis of idiopathic Parkinson disease of Hoehn and Yahr stage III-V and those with Parkinson plus syndromes were assessed for motor and nonmotor symptoms, quality of life, and functional performance. Logistic regression was used to investigate predictors of hospital admission over the subsequent 2 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0891988719868309DOI Listing
March 2020
3 Reads
2.242 Impact Factor

Social perceptual function in parkinson's disease: A meta-analysis.

Neurosci Biobehav Rev 2019 09 20;104:255-267. Epub 2019 Jul 20.

School of Psychology, University of Queensland, Brisbane, Australia.

Social perceptual impairment is a common presenting feature of Parkinson's disease (PD) that has the potential to contribute considerably to disease burden. The current study reports a meta-analytic integration of 79 studies which shows that, relative to controls, PD is associated with a moderate emotion recognition deficit (g = -0.57, K = 73), and that this deficit is robust and almost identical across facial and prosodic modalities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neubiorev.2019.07.011DOI Listing
September 2019
1 Read

Introduction and classical environmental risk factors for Parkinson.

Authors:
C Tranchant

Rev Neurol (Paris) 2019 Dec 18;175(10):650-651. Epub 2019 Jun 18.

Service de neurologie, hôpital de Hautepierre, 1, avenue Molière, 67000 Strasbourg, France. Electronic address:

Several environmental toxics are known to induce or to increase occurrence of Parkinson disease while other toxics can provoke basal ganglia necrosis and dopa resistant parkinsonism. After this introduction, the relationship between environment and parkinsonism will be illustrated by 3 short papers: interaction gene-environment, manganese induced Parkinsonism and the Caribbean Food toxins Parkinson plus syndromes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neurol.2019.04.006DOI Listing
December 2019
2 Reads

Genome-wide survey of copy number variants finds MAPT duplications in progressive supranuclear palsy.

Mov Disord 2019 07 6;34(7):1049-1059. Epub 2019 May 6.

Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, UK.

Background: Progressive supranuclear palsy is a neurodegenerative tauopathy manifesting clinically as a progressive akinetic-rigid syndrome. In this study, we sought to identify genetic variants influencing PSP susceptibility through a genome-wide association analysis of a cohort of well-characterized patients who had participated in the Neuroprotection and Natural History in Parkinson Plus Syndromes and Blood Brain Barrier in Parkinson Plus Syndromes studies.

Methods: We genotyped single-nucleotide polymorphisms in 283 PSP cases from the United Kingdom, Germany, and France and compared these with genotypes from 4472 controls. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/mds.27702
Publisher Site
http://dx.doi.org/10.1002/mds.27702DOI Listing
July 2019
34 Reads

A Comparison of Pain between Parkinson's Disease and Multiple System Atrophy: A Clinical Cross-Sectional Survey.

Pain Res Manag 2019 22;2019:3150306. Epub 2019 Jan 22.

Department of Neurology, Provincial Hospital Affiliated to Anhui Medical University, Hefei, Anhui 230000, China.

Background: Pain is frequent in Parkinson's disease (PD) and Parkinson-plus syndrome. This study aimed to assess the prevalence, characteristics, therapy (especially the effect of dopaminergic therapy), and associated symptoms of pain in Parkinson's disease and multiple system atrophy (MSA) patients.

Methods: Seventy-one PD patients, sixty-five MSA patients, and forty age-matched healthy controls were enrolled and evaluated by using the German pain questionnaire and visual analogue scale (VAS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2019/3150306DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362482PMC
June 2019
12 Reads
1.390 Impact Factor

Self-reported urinary impairment identifies 'fast progressors' in terms of neuronal loss in multiple system atrophy.

Auton Neurosci 2019 03 14;217:1-6. Epub 2018 Dec 14.

Facultad de Medicina, Universidad de Chile, Santos Dummont 999, Santiago, Chile.

Introduction: MSA is an adult-onset, sporadic, progressive parkinsonian syndrome characterised by the presence of akinesia, cerebellar dysfunction, autonomic failure and pyramidal signs. Annualized-whole-brain atrophy rate (a-WBAR) is an informative way to quantify disease progression. In this longitudinal work we investigate the correlations of a-WBAR with clinical scales for motor impairment, autonomic disability and cognitive decline in MSA and explore how atrophy progresses within the brain. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.autneu.2018.12.003DOI Listing
March 2019
22 Reads

Early perfusion and dopamine transporter imaging using F-FP-CIT PET/CT in patients with parkinsonism.

Am J Nucl Med Mol Imaging 2018 20;8(6):360-372. Epub 2018 Dec 20.

Department of Nuclear Medicine, Kyungpook National University Hospital Daegu, Republic of Korea.

Combined use of F-N-(3-fluoropropyl)-2β-carboxymethoxy-3β-(4-iodophenyl)nortropane (FP-CIT) for dopamine transporter imaging and F-fludeoxyglucose (FDG) for glucose metabolism shows good diagnostic performance for differential diagnosis of Parkinson disease (PD) and Parkinson plus syndrome (multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, and dementia with Lewy bodies). A recent study showed that F-FP-CIT positron emission tomography (PET) with early perfusion imaging is useful for the differential diagnosis of PD and Parkinson plus syndrome with lower radiation exposure, time, and cost. In this review, we summarize the advantages of using F-FP-CIT PET for perfusion and dopamine transporter imaging, as well as clinical features useful for the differential diagnosis of PD and Parkinson plus syndrome. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6334208PMC
December 2018
7 Reads

Glucose metabolic brain patterns to discriminate amyotrophic lateral sclerosis from Parkinson plus syndromes.

EJNMMI Res 2018 Dec 13;8(1):110. Epub 2018 Dec 13.

Department of Nuclear Medicine and Molecular Imaging, Division of Nuclear Medicine, KU Leuven, Herestraat 49, 3000, Leuven, Belgium.

Background: F-FDG brain PET measures metabolic changes in neurodegenerative disorders and may discriminate between different diseases even at an early stage. The objective of this study was to classify patients with amyotrophic lateral sclerosis (ALS) and Parkinson plus syndromes (PP). To this end, different approaches were evaluated using generalized linear models and corresponding glucose metabolic brain patterns. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s13550-018-0458-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6292827PMC
December 2018
8 Reads

Progress in the treatment of Parkinson-Plus syndromes.

Parkinsonism Relat Disord 2019 02 3;59:101-110. Epub 2018 Oct 3.

UC San Diego Department of Neurosciences, Parkinson and Other Movement Disorder Center, La Jolla, CA, USA. Electronic address:

Progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), multiple system atrophy (MSA), and dementia with Lewy bodies (DLB) are the four major proteinopathic neurodegenerative disorders. Currently, there are no disease modifying therapies for these disorders. However, better understanding of the etiopathogenic mechanisms of these disorders has allowed the development of novel therapeutic approaches. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S13538020183043
Publisher Site
http://dx.doi.org/10.1016/j.parkreldis.2018.10.006DOI Listing
February 2019
23 Reads

What a neurologist should know about PET and SPECT functional imaging for parkinsonism: A practical perspective.

Parkinsonism Relat Disord 2019 02 30;59:93-100. Epub 2018 Aug 30.

Univ Lyon, Institut des Sciences Cognitives Marc Jeannerod, CNRS, UMR 5229, F-69675, Bron, France; Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie C, Centre Expert Parkinson, Lyon, France; Univ Lyon, Faculté de Médecine et de Maïeutique Lyon Sud Charles Mérieux, F-69921, Oullins, France.

The diagnosis of a parkinsonian syndrome based on clinical criteria remains sometimes difficult, especially at disease onset. Brain or heart molecular imaging techniques (SPECT or PET) can provide a major help to improve and speed up diagnosis, influencing treatment strategies. Presynaptic dopaminergic imaging using either [F]-Dopa PET or I -2β-Carbomethoxy-3β-(4-Iodophenyl)- N-(3-Fluoropropyl) Nortropane ([I]-Ioflupane)SPECT demonstrates or rules out the presence of a dopaminergic degenerative process. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2018.08.016DOI Listing
February 2019
7 Reads

Jean-Martin Charcot and Parkinson's disease: Teaching and teaching materials.

Authors:
O Walusinski

Rev Neurol (Paris) 2018 Sep - Oct;174(7-8):491-505. Epub 2018 Apr 10.

Cabinet Privé, 20 rue de Chartres, 28160 Brou, France. Electronic address:

James Parkinson's 1817 seminal article was not well known in France until 1861, when Jean-Martin Charcot and his friend, Alfred Vulpian, published a detailed description in French of paralysis agitans. Their article provided clinical information to help French physicians make an accurate diagnosis by considering gait, shaking and rigidity as well as masked facies. As Charcot always had a strong desire to teach, this article describes his lessons on Parkinson's disease from 1868 to 1888, and also examines the teaching approach he used to pass on his latest findings to his students and colleagues. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neurol.2017.08.005DOI Listing
December 2018
10 Reads

99mTc-TRODAT-1 SPECT/CT imaging as a complementary biomarker in the diagnosis of parkinsonian syndromes.

Nucl Med Commun 2018 Apr;39(4):312-318

Neurology, Postgraduate Institute of Medical Education and Research, Chandigarh, Punjab, India.

Introduction: Parkinson's disease (PD) and Parkinson plus syndromes (PPS) are neurodegenerative movement disorders caused by loss of dopamine in the basal ganglia. The diagnosis of both PD and PPS is complex as it is made solely on the basis of clinical features, with no established imaging modality to aid in the diagnosis. Technetium-99m-labeled tropane derivative (Tc-TRODAT-1) binds to the dopamine transporters present in the presynaptic membrane of the dopaminergic nerve terminal. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00006231-201804000-0000
Publisher Site
http://dx.doi.org/10.1097/MNM.0000000000000802DOI Listing
April 2018
28 Reads
1.371 Impact Factor

Myoclonus in the elderly: A retrospective analysis of clinical and electrophysiological characteristics of patients referred to an electrophysiology laboratory.

Parkinsonism Relat Disord 2018 04 26;49:22-27. Epub 2017 Dec 26.

Department of Neurology, Cerrahpaşa School of Medicine, Istanbul University, Turkey.

Background And Objective: Late-onset myoclonus in the elderly is mainly related to dementia or systemic disease. In this report, we aimed to investigate the clinical and electrophysiological features of patients with late-onset myoclonus.

Patients And Method: We retrospectively assessed the medical records of patients who were referred to our electromyography laboratory. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2017.12.026DOI Listing
April 2018
8 Reads

Clinical Profile of Cognitive Decline in Patients with Parkinson's Disease, Progressive Supranuclear Palsy, and Multiple System Atrophy.

J Neurosci Rural Pract 2017 Oct-Dec;8(4):562-568

Department of Medicine, Garg Hospital, Faridkot, Punjab, India.

Background: There are very less data on the comparison between the cognitive profile in Parkinson's disease (PD) and Parkinson's-plus groups, especially in India.

Aims: The aim of this study is to compare the cognitive profile across PD, progressive supranuclear palsy (PSP), and multiple system atrophy (MSA) groups and compare them using Mini-Mental State Examination (MMSE), frontal assessment battery (FAB), and verbal fluency tests.

Settings And Design: This was a cross-sectional study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/jnrp.jnrp_154_17DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709878PMC
December 2017
14 Reads

CSF biomarkers β-amyloid, tau proteins and a-synuclein in the differential diagnosis of Parkinson-plus syndromes.

J Neurol Sci 2017 Nov 28;382:91-95. Epub 2017 Sep 28.

1st Department of Neurology, National and Kapodistrian University of Athens, Eginition Hospital, 72-74 Vassilisis Sofias Avenue, Athens P.C.:11528, Greece.

Introduction: Differential diagnosis of Parkinson-plus patients (PSP, CBD, MSA) and Parkinson's disease (PD) patients is often not straightforward, particularly in atypical cases or at the initial stages of the diseases. Classic CSF biomarkers (amyloid-beta - Aβ, tau protein - τ and phosphorylated tau protein - τ) are established biomarkers in the diagnosis of Alzheimer's disease (AD). CSF a-synuclein (α-syn) has emerged as a promising biomarker in patients with Parkinsonism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2017.09.039DOI Listing
November 2017
33 Reads

Phenotypic Variants of Patients with Progressive Supranuclear Palsy.

Authors:
Murat Gültekın

Noro Psikiyatr Ars 2020 Mar 8;57(1):61-64. Epub 2017 Nov 8.

Department of Neurology, Erciyes University School of Medicine, Kayseri, Turkey.

Introduction: Progressive supranuclear palsy (PSP) is a commonly observed disease among Parkinson plus syndromes, and its early and accurate diagnosis is usually not possible. PSP is currently reported to have eight different subtypes. This study aims to determine the phenotypic subtypes of PSP and reveal their accompanying characteristics. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5152/npa.2017.22771DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7024825PMC

Atypical parkinsonian syndromes: a general neurologist's perspective.

Eur J Neurol 2018 01 28;25(1):41-58. Epub 2017 Sep 28.

Department of Neurology, Mayo Clinic, Jacksonville, FL, USA.

The differential diagnosis of atypical parkinsonian syndromes is challenging. These severe and often rapidly progressive neurodegenerative disorders are clinically heterogeneous and show significant phenotypic overlap. Here, clinical, imaging, neuropathological and genetic features of multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration and frontotemporal lobar degeneration (FTLD) are reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ene.13412DOI Listing
January 2018
29 Reads

Can loss of the swallow tail sign help distinguish between Parkinson Disease and the Parkinson-Plus syndromes?

Clin Imaging 2017 Jul - Aug;44:66-69. Epub 2017 Apr 20.

Department of Radiology, Northwestern University Feinberg School of Medicine, Chicago, IL, United States. Electronic address:

Purpose: To determine if loss of the swallow tail sign (STS) can distinguish Parkinson Disease (PD) from the Parkinson-Plus syndromes.

Methods: Twenty-five patients with PD, 21 with Parkinson-Plus syndromes, and 14 control patients were included. Presence of the STS was assessed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clinimag.2017.04.005DOI Listing
December 2017
25 Reads

Imaging biomarkers in Parkinson's disease and Parkinsonian syndromes: current and emerging concepts.

Transl Neurodegener 2017 28;6. Epub 2017 Mar 28.

Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto, Canada.

Two centuries ago in 1817, James Parkinson provided the first medical description of Parkinson's disease, later refined by Jean-Martin Charcot in the mid-to-late 19th century to include the atypical parkinsonian variants (also termed, Parkinson-plus syndromes). Today, Parkinson's disease represents the second most common neurodegenerative disorder with an estimated global prevalence of over 10 million. Conversely, atypical parkinsonian syndromes encompass a group of relatively heterogeneous disorders that may share some clinical features with Parkinson's disease, but are uncommon distinct clinicopathological diseases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s40035-017-0076-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5370489PMC
March 2017
30 Reads

Predictors of survival in progressive supranuclear palsy and multiple system atrophy: a systematic review and meta-analysis.

J Neurol Neurosurg Psychiatry 2017 05 1;88(5):402-411. Epub 2017 Mar 1.

Hurstwood Park Neurological Centre, Brighton and Sussex University Hospitals, Brighton, UK.

Objective: To undertake a systematic review and meta-analysis of studies that investigated prognostic factors and survival in patients with progressive supranuclear palsy (PSP) and multiple system atrophy (MSA).

Methods: Publications of at least 10 patients with a likely or confirmed diagnosis of PSP or MSA were eligible for inclusion. Methodological quality was rated using a modified version of the Quality in Prognostic Studies tool. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jnnp-2016-314956DOI Listing
May 2017
9 Reads

Imagerie cérébrale dans les syndromes parkinsoniens.

Presse Med 2017 Mar 28;46(2 Pt 1):202-209. Epub 2016 Dec 28.

Université de Lyon, université Claude-Bernard Lyon I, faculté de médecine Lyon Sud Charles-Mérieux, Lyon, France; Hospices civils de Lyon, hôpital neurologique Pierre-Wertheimer, service de neurologie C, centre expert parkinson, Lyon, France; CNRS, centre de neurosciences cognitives, UMR 5229, Bron, France. Electronic address:

Role of brain imaging for Parkinsonism T brain MRI is normal in Pakinson's disease. Brain MRI is useless when clinical presentation is typical of idiopathic Parkinson's disease. Brain MRI is the exam of choice for differentiating idiopathic Parkinson's disease and atypical parkinsonism. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.lpm.2016.09.025DOI Listing
March 2017
20 Reads

Pain in Extrapyramidal Neurodegenerative Diseases.

Clin J Pain 2017 07;33(7):635-639

*Department of Neurology, Movement Disorder Clinic, Rabin Medical Center, Beilinson Hospital, Petach Tikva ‡Movement Disorders Unit, Tel Aviv Sourasky Medical Center †Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.

Objective: Pain is one of the most common nonmotor symptoms of Parkinson disease (PD) and other Parkinson plus syndromes, with a major effect on quality of life. The aims of the study were to examine the prevalence and characteristics of pain in PD and other Parkinson plus syndromes and patient use and response to pain medications.

Methods: The cohort consisted of 371 patients: 300 (81%) with PD and 71 (19%) with Parkinson plus syndromes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/AJP.0000000000000437DOI Listing
July 2017
21 Reads

Progressive Supranuclear Palsy and Corticobasal Degeneration: Pathophysiology and Treatment Options.

Curr Treat Options Neurol 2016 Sep;18(9):42

Department of Clinical Neuroscience, UCL Institute of Neurology, Queen Square, London, UK.

Opinion Statement: There are currently no disease-modifying treatments for progressive supranuclear palsy (PSP) or corticobasal degeneration (CBD), and no approved pharmacological or therapeutic treatments that are effective in controlling their symptoms. The use of most pharmacological treatment options are based on experience in other disorders or from non-randomized historical controls, case series, or expert opinion. Levodopa may provide some improvement in symptoms of Parkinsonism (specifically bradykinesia and rigidity) in PSP and CBD; however, evidence is conflicting and where present, benefits are often negligible and short lived. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11940-016-0422-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4985534PMC
September 2016
44 Reads

Single-photon emission tomography.

Handb Clin Neurol 2016 ;135:241-250

Division of Nuclear Medicine, University Hospital Leuven and KU Leuven, Leuven, Belgium. Electronic address:

Single-photon emission computed tomography (SPECT) is a functional nuclear imaging technique that allows visualization and quantification of different in vivo physiologic and pathologic features of brain neurobiology. It has been used for many years in diagnosis of several neurologic and psychiatric disorders. In this chapter, we discuss the current state-of-the-art of SPECT imaging of brain perfusion and dopamine transporter (DAT) imaging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/B978-0-444-53485-9.00013-1DOI Listing
February 2017
13 Reads

DCTN1 p.K56R in progressive supranuclear palsy.

Parkinsonism Relat Disord 2016 07 23;28:56-61. Epub 2016 Apr 23.

Centre for Applied Neurogenetics, Djavad Mowafaghian Centre for Brain Health, Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada. Electronic address:

Introduction: Mutations in dynactin DCTN1 (p150(glued)) have previously been linked to familial motor neuron disease or Perry syndrome (PS) consisting of depression, parkinsonism and hypoventilation.

Methods: We sequenced DCTN1 in 636 Caucasian patients with parkinsonism (Parkinson's disease and Parkinson-plus syndromes) and 508 healthy controls. Variants (MAF < 0. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2016.04.025DOI Listing
July 2016
38 Reads

Autoimmune atypical parkinsonism - A group of treatable parkinsonism.

J Neurol Sci 2016 Mar 13;362:40-6. Epub 2016 Jan 13.

Department of Neurology, Amrita Institute of Medical Sciences, Ponekkara PO, Kochi 682041, Kerala, India.

Background: Immunological causes of atypical parkinsonism/Parkinson plus syndromes are rare.

Objective: To study the clinical and laboratory features and treatment outcome of autoimmune atypical parkinsonism.

Methods: Retrospective case series. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2016.01.006DOI Listing
March 2016
6 Reads

Progress in unraveling the genetic etiology of Parkinson disease in a genomic era.

Trends Genet 2015 Mar 20;31(3):140-9. Epub 2015 Feb 20.

Neurodegenerative Brain Diseases Group, Department of Molecular Genetics, VIB, Antwerp, Belgium; Laboratory of Neurogenetics, Institute Born Bunge, University of Antwerp, Antwerp, Belgium. Electronic address:

Parkinson disease (PD) and Parkinson-plus syndromes are genetically heterogeneous neurological diseases. Initial studies into the genetic causes of PD relied on classical molecular genetic approaches in well-documented case families. More recently, these approaches have been combined with exome sequencing and together have identified 15 causal genes. Read More

View Article

Download full-text PDF

Source
http://www.cell.com/trends/genetics/pdf/S0168-9525(15)00015-
Web Search
http://linkinghub.elsevier.com/retrieve/pii/S016895251500015
Publisher Site
http://dx.doi.org/10.1016/j.tig.2015.01.004DOI Listing
March 2015
7 Reads

Impaired detrusor contractility is the pathognomonic urodynamic finding of multiple system atrophy compared to idiopathic Parkinson's disease.

Parkinsonism Relat Disord 2015 Mar 15;21(3):205-10. Epub 2014 Dec 15.

Department of Urology, SMG-SNU Boramae Medical Center, Donggak-gu, Boramae-ro 5 Gil, 20, Seoul 156-707, Republic of Korea. Electronic address:

Introduction: To investigate differences in urodynamic parameters between two groups: Parkinson's disease (PD) and multiple system atrophy (MSA) patients.

Methods: A retrospective study was performed in patients with PD and MSA who presented to three referral centers between 2005 and 2012. Patients referred to the urology department for lower urinary tract symptoms underwent urodynamic studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.parkreldis.2014.12.003DOI Listing
March 2015
17 Reads

Deep brain stimulation in multiple system atrophy mimicking idiopathic Parkinson's disease.

Case Rep Neurol 2014 Sep 23;6(3):232-7. Epub 2014 Oct 23.

Department of Neurosurgery, John Radcliffe Hospital, Oxford, UK.

Deep brain stimulation (DBS) is approved for idiopathic Parkinson's disease (IPD) but has a poor evidence base in Parkinson-plus syndromes such as multiple system atrophy (MSA). We describe the clinical and neuropathological findings in a man who was initially diagnosed with IPD, in whom DBS was unsuccessful, and in whom MSA was unexpectedly diagnosed at a subsequent autopsy. This case report highlights that DBS is often unsuccessful in MSA and also demonstrates that MSA can masquerade as IPD, which may explain treatment failure in a small group of patients apparently suffering from Parkinson's disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000368571DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4250004PMC
September 2014
39 Reads

Trial of Zolpidem, Eszopiclone, and Other GABA Agonists in a Patient with Progressive Supranuclear Palsy.

Case Rep Med 2014 16;2014:107064. Epub 2014 Sep 16.

Department of Internal Medicine, Stanford University Medical Center, 300 Pasteur Drive, Palo Alto, CA 94305, USA ; Palo Alto Medical Foundation, 795 El Camino Real, Palo Alto, CA 94301, USA.

Progressive supranuclear palsy (PSP) is a progressive, debilitating neurodegenerative disease of the Parkinson-plus family of syndromes. Unfortunately, there are no pharmacologic treatments for this condition, as most sufferers of the classic variant respond poorly to Parkinson medications such as levodopa. Zolpidem, a gamma aminobutyric acid (GABA) agonist specific to the α-1 receptor subtype, has been reported to show improvements in symptoms of PSP patients, including motor dysfunction, dysarthria, and ocular disturbances. Read More

View Article

Download full-text PDF

Source
http://www.hindawi.com/journals/crim/2014/107064/
Publisher Site
http://dx.doi.org/10.1155/2014/107064DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4209775PMC
November 2014
17 Reads

Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both α-synucleinopathy and tauopathy.

Neuropsychiatr Dis Treat 2014 5;10:1003-9. Epub 2014 Jun 5.

IRCCS San Giovanni di Dio Fatebenefratelli, Brescia, Italy.

Transdermal rotigotine (RTG) is a non-ergot dopamine agonist (D3>D2>D1), and is indicated for use in early and advanced Parkinson's disease (PD). RTG patch has many potential advantages due to the immediacy of onset of the therapeutic effect. Of note, intestinal absorption is not necessary and drug delivery is constant, thereby avoiding drug peaks and helping patient compliance. Read More

View Article

Download full-text PDF

Source
http://www.dovepress.com/rotigotine-is-safe-and-efficacious-
Publisher Site
http://dx.doi.org/10.2147/NDT.S64015DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4051815PMC
June 2014
28 Reads

Davunetide in patients with progressive supranuclear palsy: a randomised, double-blind, placebo-controlled phase 2/3 trial.

Lancet Neurol 2014 Jul 27;13(7):676-85. Epub 2014 May 27.

Celerion, Lincoln, NE, USA.

Background: In preclinical studies, davunetide promoted microtubule stability and reduced tau phosphorylation. Because progressive supranuclear palsy (PSP) is linked to tau pathology, davunetide could be a treatment for PSP. We assessed the safety and efficacy of davunetide in patients with PSP. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1474-4422(14)70088-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4129545PMC
July 2014
70 Reads

The value of novel MRI techniques in Parkinson-plus syndromes: diffusion tensor imaging and anatomical connectivity studies.

Rev Neurol (Paris) 2014 Apr 20;170(4):266-76. Epub 2014 Mar 20.

Service de neurologie et pathologie du mouvement, hôpital Salengro, CHRU de Lille, EA 1046, département de pharmacologie médicale, université Lille Nord de France, 1, place de Verdun, 59045 Lille cedex, France.

Conventional MRI is a well-described, highly useful tool for the differential diagnosis of degenerative parkinsonian syndromes. Nevertheless, the observed abnormalities may only appear in late-stage disease. Diffusion tensor imaging (DTI) can identify microstructural changes in brain tissue integrity and connectivity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neurol.2013.10.013DOI Listing
April 2014
16 Reads

The applause sign in Parkinson's disease patients is related to dysexecutive syndrome.

J Clin Neurosci 2013 Dec 20;20(12):1734-6. Epub 2013 Aug 20.

Department of Neurology, Osijek University Hospital Center, J. Huttlera 4, HR-31000 Osijek, Croatia. Electronic address:

Recent publications report that a positive applause sign is not only present in patients with neurodegenerative diseases where the subcortical structures are affected but also in patients with cortical dementia. The nature of this sign remains unknown. This study aimed to determine the frequency of the applause sign and its correlation with cognitive impairment in patients with idiopathic Parkinson's disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jocn.2013.02.024DOI Listing
December 2013
14 Reads

Surgical management of airway dysfunction in Parkinson's disease compared with Parkinson-plus syndromes.

Ann Otol Rhinol Laryngol 2013 May;122(5):294-8

New York Center for Voice and Swallowing Disorders, St Luke's Roosevelt Medical Center, New York, NY 10019, USA.

Objectives: We sought to compare the laryngeal symptoms of Parkinson's disease (PD) with those of multiple system atrophy (MSA), a Parkinson-plus syndrome; to review the differences in surgical management of upper airway dysfunction between patients with PD and those with MSA; and to present a treatment algorithm for management of upper airway disorders in patients with PD and MSA.

Methods: We analyzed the airway manifestations of each disease, including clinical and physiological test results and management outcomes, in a case series of 30 patients (24 with PD and 6 with MSA).

Results: Vocal fold atrophy causing bowing with a midfold glottic gap was common in patients with PD. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/000348941312200502DOI Listing
May 2013
36 Reads

Clinical utility of DaTscan™ (123I-Ioflupane Injection) in the diagnosis of Parkinsonian Syndromes.

Degener Neurol Neuromuscul Dis 2013 27;3:33-39. Epub 2013 Jun 27.

Centre for Neuroinflammation and Neurodegeneration, Imperial College London, London, United Kingdom,

The diagnosis of movement disorders including Parkinsonian syndromes and essential tremor is mainly clinical. The most common diagnostic errors for Parkinson's disease include misdiagnoses such as Parkinson plus syndromes and cases of essential tremor. In this article, we discuss the clinical utility of DaTscan™ (123I-Ioflupane injection) and its diagnostic value in Parkinson's disease and the other Parkinsonian syndromes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/DNND.S19807DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6065574PMC
June 2013
5 Reads

Levodopa Responsiveness in Adult-onset Lower Limb Dystonia is Associated with the Development of Parkinson's Disease.

Tremor Other Hyperkinet Mov (N Y) 2013 18;3. Epub 2013 Apr 18.

Mayo Clinic, Rochester, Minnesota, United States of America.

Background: Adult-onset primary lower limb dystonia (AOPLLD) has been reported as an early sign of Parkinson's disease (PD) or Parkinson-plus syndrome in case series. No prior systematic analysis has assessed clinical clues predicting later development of PD or Parkinson-plus syndrome.

Methods: We identified patients with AOPLLD from medical records. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629864PMC
http://dx.doi.org/10.7916/D8VD6X5MDOI Listing
April 2013
12 Reads

Accuracy of the National Institute for Neurological Disorders and Stroke/Society for Progressive Supranuclear Palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy.

Mov Disord 2013 Apr 21;28(4):504-9. Epub 2013 Feb 21.

Department of Neurology, Philipps Universität, Marburg, Germany.

Autopsy is the diagnostic gold standard for progressive supranuclear palsy (PSP). The National Institute of Neurological Disorders and Stroke and Society for Progressive Supranuclear Palsy (NINDS-SPSP) criteria for the clinical diagnosis of "probable" PSP are thought to possess high specificity and low sensitivity. The NINDS-SPSP criteria for "possible" PSP are considered to increase sensitivity at the expense of specificity. Read More

View Article

Download full-text PDF

Source
http://www.expy.cz/userfiles/file/PSP%20guidelines.pdf
Web Search
http://doi.wiley.com/10.1002/mds.25327
Publisher Site
http://dx.doi.org/10.1002/mds.25327DOI Listing
April 2013
42 Reads

[Vascular or "lower body Parkinsonism": rise and fall of a diagnosis].

Authors:
Imre Szirmai

Ideggyogy Sz 2011 Nov;64(11-12):385-93

Semmelweis Egyetem, Neurológiai Klinika, Budapest.

Unlabelled: The "arteriosclerotic parkinsonism", which is called vascular parkinsonism (VP), was first described by Critchley'. The broad based slow gait, reduced stride lenght, start hesitation, freezing and paratonia was mentioned as "lower body parkinsonism" (LBP) which can be associated by slow speech, dysexecutive syndrome, and hand tremor of predominantly postural character. In VP the DAT-scan proved normal dopamine content of the striatum in contrast with Parkinson's disease (PD). Read More

View Article

Download full-text PDF

Source
November 2011
36 Reads

Serum iron, vitamin B12 and folic acid levels in Parkinson's disease.

Neurochem Res 2012 Jul 26;37(7):1436-41. Epub 2012 Feb 26.

Ankara Numune Egitim ve Arastirma Hastanesi, Noroloji Klinigi, Talatpasa, Bulvari, Samanpazari, Ankara, Turkey.

We aimed to investigate possible associations between systemic iron metabolism deficiency and Parkinson's disease, and also to research any possible correlations between stage of the disease and vitamin B12 and folic acid levels. 33 male and 27 female patients diagnosed with idiopathic Parkinson's disease and 22 male and 20 female age- and sex-matched controls were enrolled in the study. Having the diagnosis of secondary Parkinsonism or Parkinson plus syndromes, and for the females, not being in the menopausal stage were considered as exclusion criteria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11064-012-0729-xDOI Listing
July 2012
7 Reads